March 12, 2020 06:14 AM EDTUpdated 07:12 AM
Financing

Har­bour Bio­Med nets $75M in Se­ries B+ as first glob­al tri­al gets un­der­way

Jason Mast

Editor

Near­ly two years af­ter draw­ing an $85 mil­lion Se­ries B, Shang­hai-based Har­bour Bio­Med has an­nounced a new large fund­ing round.

In what they’re billing …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Up­dat­ed: No­vo’s 23% weight loss with Ca­griSe­ma falls short of high ex­pec­ta­tions, new tri­al planned

Sofinno­va out­lines $550M fund af­ter IPOs and M&A deals

Ex­clu­sive: Flori­da can­cer biotech rais­es $100M Se­ries A

Ac­cel­er­at­ed ap­proval brings Pfiz­er's BRAF in­hibitor to first-line pa­tients

FDA ap­proves Hu­ma­cyte’s lab-grown blood ves­sels in mile­stone for re­gen­er­a­tive med­i­cine

A service from the Financial Times